PT-141 (Bremelanotide) Patent Status and Generic Timeline

How Bremelanotide Works: Mechanism of Action

Bremelanotide is a cyclic heptapeptide that activates melanocortin-4 receptors (MC4R) in the central nervous system, producing its effects on sexual desire through hypothalamic signaling pathways rather than through peripheral vascular mechanisms [1]. This sets it apart from phosphodiesterase-5 inhibitors like sildenafil. The drug binds MC4R and, to a lesser degree, MC3R and MC1R, triggering downstream dopaminergic and oxytocinergic circuits involved in sexual arousal and motivation [2].

The FDA approved bremelanotide on June 21, 2019, under the brand name Vyleesi, based primarily on the RECONNECT phase 3 program. That approval was specifically for acquired, generalized HSDD in premenopausal women [3]. It is administered as a 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than eight doses per month.

Understanding this mechanism matters for the patent discussion because several of Palatin's patent claims cover not only the compound itself but also specific MC4R-mediated therapeutic applications and dosing regimens.

Key Efficacy Data from RECONNECT

The RECONNECT program consisted of two replicate, randomized, double-blind, placebo-controlled trials (Study 301 and Study 302) enrolling a combined 1,247 premenopausal women with HSDD [3]. Participants self-administered bremelanotide 1.75 mg or placebo subcutaneously as needed over 24 weeks.

Both trials met their co-primary endpoints. In Study 301, bremelanotide produced a statistically significant increase in the Female Sexual Function Index desire domain score (change from baseline: +0.5 vs. +0.2 for placebo). Study 302 showed similar results. The Female Sexual Distress Scale (FSDS-DAO Item 13) also improved significantly in both studies, with reductions in distress scores roughly double those seen with placebo [3].

Nausea was the most common adverse event, affecting approximately 40% of bremelanotide-treated patients versus 1% on placebo. About 13% discontinued due to nausea. Transient facial flushing and injection-site reactions were also reported. Blood pressure increased modestly (systolic rise of approximately 3 mmHg) and returned to baseline within 12 hours post-dose, leading to a contraindication in patients with uncontrolled hypertension or known cardiovascular disease [4].

These efficacy and safety data form the clinical foundation that any future generic applicant will need to reference when filing an abbreviated application.

Patent Portfolio Protecting Bremelanotide

Palatin Technologies developed bremelanotide from the synthetic melanocortin peptide Melanotan II. The company built a patent estate covering several dimensions of the molecule and its therapeutic use. Three categories of patents are relevant here.

Composition-of-matter patents. These cover the bremelanotide molecule itself, including its cyclic heptapeptide structure. Composition patents provide the broadest protection because they prevent any use of the compound, regardless of indication or formulation. Palatin's core composition patents were filed in the early 2000s, with 20-year terms placing their base expirations in the mid-2020s. Patent term adjustments (PTA) and patent term extensions (PTE) granted by the USPTO under the Hatch-Waxman Act may push some of these expirations to 2027 or 2028.

Method-of-use patents. These claim specific therapeutic applications, such as treating HSDD or female sexual dysfunction via MC4R activation. Method-of-use patents can extend protection beyond composition patent expiration, but they are narrower in scope. A generic manufacturer could potentially design around these claims by seeking approval for a different indication, though the practical market for bremelanotide is limited to sexual desire disorders.

Formulation and delivery patents. AMAG Pharmaceuticals (which licensed U.S. commercial rights from Palatin) holds or licenses patents related to the autoinjector device and the specific subcutaneous formulation. These device-related patents can complicate generic entry because an ANDA applicant must demonstrate that its delivery system is bioequivalent to the reference product.

The FDA's Orange Book lists the patents that AMAG/Palatin have submitted as covering Vyleesi. Any generic applicant filing a 505(j) ANDA must certify against each listed patent, either waiting for expiration (Paragraph III certification) or challenging validity/non-infringement (Paragraph IV certification) [5].

Regulatory Exclusivity Periods

Beyond patents, the FDA grants several forms of regulatory exclusivity that operate independently of patent protection.

New Chemical Entity (NCE) exclusivity (5 years). Bremelanotide received NCE exclusivity upon its June 2019 approval, blocking any ANDA submission until June 2024. This period has now passed. An ANDA applicant could submit its application at any time, but approval would still be blocked by unexpired patents unless successfully challenged [5].

Clinical investigation exclusivity (3 years). If the NDA holder conducts new clinical studies supporting a supplemental approval (such as a new indication, new dosage form, or new patient population), a separate 3-year exclusivity period could attach to that new use. As of May 2026, no supplemental NDAs for bremelanotide have been approved that would trigger additional clinical investigation exclusivity.

Orphan drug exclusivity. Not applicable. Bremelanotide was not granted orphan designation for HSDD.

Pediatric exclusivity (6 months). If Palatin or AMAG completed FDA-requested pediatric studies, an additional 6 months of exclusivity could be added to existing patents and exclusivities. No pediatric exclusivity has been publicly reported for bremelanotide.

The practical result: regulatory exclusivity alone no longer blocks generic entry. Patents are the remaining barrier.

Projected Generic Entry Timeline

Estimating when a generic bremelanotide will reach the market requires weighing several variables.

Patent expiration dates. The latest-expiring Orange Book patents for Vyleesi extend into the late 2020s. With PTA/PTE adjustments, some claims may not expire until 2028 or 2029. If a generic company files a Paragraph IV challenge and prevails in litigation, it could enter the market earlier, but patent litigation in the pharmaceutical industry typically takes 2.5 to 4 years from ANDA filing to resolution [6].

Commercial viability. Generic entry depends on whether the market is large enough to justify the investment. Vyleesi's commercial performance has been modest. AMAG reported limited uptake, and the product's commercial rights have changed hands. The high cost per dose (approximately $900 to $1,000), limited insurance coverage, and nausea-related discontinuation rates have constrained the patient population. A small market may discourage generic developers from investing in bioequivalence studies and ANDA litigation.

Peptide manufacturing complexity. Bremelanotide is a synthetic peptide, not a small molecule. Generic peptide manufacturing requires solid-phase or liquid-phase peptide synthesis with tight quality controls. The FDA's guidance on demonstrating bioequivalence for peptide drugs has evolved, and the agency may require additional characterization studies beyond standard small-molecule ANDA requirements [7]. This complexity adds cost and time.

No Paragraph IV filings reported. As of May 2026, no generic manufacturer has publicly announced an ANDA filing with a Paragraph IV certification against Vyleesi patents. The absence of filings suggests that generic entry before 2030 is unlikely.

A realistic projection: generic bremelanotide could become available between 2030 and 2032, assuming at least one generic developer pursues an ANDA after key patents expire and demonstrates bioequivalence to the FDA's satisfaction.

How a Generic ANDA Would Work for Bremelanotide

A company seeking to market generic bremelanotide would file a 505(j) ANDA referencing Vyleesi as the reference listed drug (RLD). The application must demonstrate pharmaceutical equivalence (same active ingredient, same route of administration, same dosage form, same strength) and bioequivalence (comparable rate and extent of absorption) [5].

For injectable peptide products, bioequivalence typically requires comparative pharmacokinetic studies showing that the generic product's AUC and Cmax fall within 80% to 125% of the reference product's values. The FDA may also require comparative assessments of peptide purity, impurity profiles, and aggregation behavior.

The generic product does not need to replicate the branded autoinjector device. It could use a different delivery system, such as a prefilled syringe, provided the route and dose remain the same. Device differences could affect patient acceptance but do not constitute a regulatory barrier.

If the ANDA includes a Paragraph IV certification against any Orange Book patent, the applicant must notify Palatin/AMAG, who then have 45 days to file a patent infringement suit. Filing suit triggers an automatic 30-month stay of FDA approval, during which the agency cannot approve the ANDA unless the court rules in the generic company's favor or the stay expires [6].

The Role of 503B Compounding Pharmacies

While no FDA-approved generic exists, some patients access bremelanotide (often referred to as PT-141) through 503B outsourcing facilities that compound the peptide. These pharmacies operate under Section 503B of the Federal Food, Drug, and Cosmetic Act, which allows them to produce compounded drugs without individual prescriptions, provided they meet current good manufacturing practice (cGMP) requirements [8].

Compounded PT-141 is significantly less expensive than branded Vyleesi, often costing $50 to $150 per dose. Compounded versions are not FDA-approved and have not undergone the same bioequivalence testing as an approved generic would.

The FDA has scrutinized compounding of commercially available drugs. Under current policy, 503B pharmacies may compound copies of commercially available products only if the drug appears on the FDA's shortage list or if clinical differences justify compounding (such as a different concentration or preservative-free formulation) [8]. Whether compounded PT-141 will face enforcement action as the FDA's oversight of compounding pharmacies intensifies remains uncertain.

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has noted: "Access to bremelanotide remains a significant barrier for many women with HSDD. The cost of Vyleesi, combined with limited insurance coverage, has pushed patients toward compounding pharmacies, which raises questions about quality consistency."

Patent Challenges and the Broader Generic Peptide Market

The peptide drug generic market is still developing. The FDA's 2021 draft guidance on demonstrating bioequivalence for certain synthetic peptide drug products provided a clearer regulatory pathway, but peptide ANDAs remain more complex and expensive than traditional small-molecule applications [7].

Several precedents exist. Generic versions of synthetic peptides like octreotide (Sandostatin) and leuprolide (Lupron) have reached the market, demonstrating that the pathway is viable. Generic teriparatide (Forteo) was approved via the 505(b)(2) pathway in 2023, providing another model for peptide generics.

The Endocrine Society's 2019 clinical practice guidelines on HSDD management list bremelanotide as a treatment option for premenopausal women, alongside flibanserin (Addyi), noting that "the choice between agents should be individualized based on patient preference, side-effect profile, and mode of administration" [9]. This guideline positioning could support continued demand for bremelanotide and, by extension, interest in generic development.

A second quote worth noting comes from the FDA's 2019 approval press release. Dr. Hylton Joffe, then-director of the FDA's Center for Drug Evaluation and Research Division of Bone, Reproductive and Urologic Products, stated: "There are few approved treatments for [HSDD] and each works in a different way. Today's approval provides women with another treatment option" [4].

What Patients Should Know Now

For patients currently prescribed Vyleesi, several practical considerations apply while waiting for potential generic availability.

Insurance coverage varies widely. Many commercial plans require prior authorization, and some exclude Vyleesi entirely. Palatin Technologies and AMAG have offered patient assistance programs, though eligibility criteria and program availability change over time.

The per-dose cost without insurance makes sustained use financially prohibitive for many patients. Women using Vyleesi at the recommended maximum of eight doses per month could face monthly costs exceeding $7,000 at list price.

Patients considering compounded PT-141 should discuss quality and sourcing with their prescriber. Not all compounding pharmacies maintain equivalent quality standards, and peptide purity can vary between facilities.

Generic entry, when it occurs, should reduce costs substantially. For reference, generic peptide products have historically entered the market at 40% to 60% below branded pricing, though the magnitude of price reduction depends on the number of generic competitors [10].

Patients with HSDD should receive a complete diagnostic workup before starting bremelanotide, including assessment for depression, relationship factors, medication side effects (particularly from SSRIs and hormonal contraceptives), and hormonal imbalances. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for female sexual interest/arousal disorder should guide diagnosis [9].